# GLP-1 Drugs and New-Onset Sleep Apnea: A UK Cohort of 47,315 Users

A UK cohort compared newly recorded sleep apnea diagnoses after GLP-1 or DPP-4 inhibitor prescriptions. See how that differs from tirzepatide treatment trials.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/glp1-sleep-apnea-treat-vs-prevent
Updated: 2026-11-15
Published: 2026-09-16

[← Research](https://buythisglp.com/research)

Evidence

# GLP-1 Drugs and New-Onset Sleep Apnea: A UK Cohort of 47,315 Users

A UK cohort found no clear difference in new obstructive sleep apnea diagnoses between adults with obesity and type 2 diabetes starting GLP-1 drugs or DPP-4 inhibitors.

Editorial profile: [Carla Medina](https://buythisglp.com/authors/carla-medina)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20264 min readUpdated November 2026

New sleep apnea diagnoses: GLP-1 vs DPP-4 inhibitors · 1.07 · 0.93 · 1.23 · 1.0 · 47,315 on a GLP-1 against 159,066 on the comparator, up to three years

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   In UK primary care records, a new diagnosis of obstructive sleep apnea was recorded at 5.8 versus 5.4 per 1,000 person-years in people starting a GLP-1 drug versus a DPP-4 inhibitor.
-   The hazard ratio was 1.07 (95% CI 0.93–1.23), so the study found no clear difference in newly recorded diagnoses.
-   Separate randomized trials found that tirzepatide reduced the severity of established obstructive sleep apnea in adults with obesity.

## What the UK cohort measured

Researchers used UK primary care records from 2007 to 2023. They identified 47,315 adults starting a GLP-1 receptor agonist and 159,066 starting a DPP-4 inhibitor. Everyone had type 2 diabetes and a BMI of at least 30 and had no prior recorded sleep apnea diagnosis. The researchers weighted the groups within BMI categories to balance measured baseline characteristics and used an as-treated analysis with up to three years of follow-up[\[1\]](https://buythisglp.com/research/glp1-sleep-apnea-treat-vs-prevent#ref-1).

There were 612 new diagnoses in the GLP-1 group and 1,197 in the DPP-4 inhibitor group. The incidence rates were 5.8 and 5.4 per 1,000 person-years, respectively. The confidence interval around the hazard ratio of 1.07 included both a lower and a higher diagnosis rate. Results were consistent across BMI groups, sex, drug type and sensitivity analyses [\[1\]](https://buythisglp.com/research/glp1-sleep-apnea-treat-vs-prevent#ref-1).

## How this differs from the treatment trials

The [SURMOUNT-OSA tirzepatide trials](https://buythisglp.com/research/do-glp1-drugs-help-sleep-apnea) used sleep studies to measure breathing events among adults with obesity who already had moderate-to-severe obstructive sleep apnea. Tirzepatide reduced events compared with placebo in both trials [\[2\]](https://buythisglp.com/research/glp1-sleep-apnea-treat-vs-prevent#ref-2). The U.S. FDA indication is for Zepbound in adults with obesity and moderate-to-severe obstructive sleep apnea [\[3\]](https://buythisglp.com/research/glp1-sleep-apnea-treat-vs-prevent#ref-3).

A clinical diagnosis in primary care can depend on who is referred and tested. It does not tell researchers exactly when apnea began. The [survey of sleep-clinic follow-up practices](https://buythisglp.com/research/nobody-is-rechecking-your-cpap) covers a separate example of how follow-up can vary after treatment and weight loss. The UK cohort compared prescriptions in routine care, so it could not isolate the effect of weight loss itself.

What the cohort can tell us about prevention

The study found no clear reduction in newly recorded sleep apnea diagnoses in the population studied. It cannot establish that the medicines prevent sleep apnea or rule out effects in other populations or over longer periods.

## Frequently asked

Do GLP-1 drugs prevent obstructive sleep apnea?

The UK cohort found no clear difference in new diagnoses between adults with obesity and type 2 diabetes starting a GLP-1 drug or a DPP-4 inhibitor. The hazard ratio was 1.07 (95% CI 0.93–1.23).

Can tirzepatide treat existing obstructive sleep apnea?

Yes. Randomized trials showed reduced apnea severity in adults with obesity and moderate-to-severe obstructive sleep apnea. The FDA approved Zepbound for this population.

Did everyone in the cohort get a sleep study?

The cohort used clinically recorded diagnoses. Researchers did not conduct standardized sleep studies for all participants, so the result can reflect differences in testing or referral.

## Sources

1.  \[1\] Khouri C, et al. (2026). Effectiveness of GLP-1 receptor agonists to prevent obstructive sleep apnea in patients with type 2 diabetes: active comparator, new user cohort study American Journal of Respiratory and Critical Care Medicine. [PMID 42745463](https://pubmed.ncbi.nlm.nih.gov/42745463/)
2.  \[2\] Malhotra A, et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity New England Journal of Medicine. [PMID 38912654](https://pubmed.ncbi.nlm.nih.gov/38912654/)
3.  \[3\] U.S. Food and Drug Administration (2026). Zepbound U.S. prescribing information FDA. [Source](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
